Gambogenic acid

Gambogenic acid (CAS No.: 173932-75-7) is a bioactive xanthone-derived natural product isolated from gamboge (Garcinia hanburyi) that has attracted significant interest as a chemical probe for epigenetic regulation and anticancer research. It functions as a covalent inhibitor of the histone methyltransferase EZH2 by specifically targeting the Cys668 residue within the catalytic SET domain, thereby suppressing enzymatic activity and promoting ubiquitination-dependent degradation of EZH2, a key regulator of chromatin remodeling implicated in multiple malignancies. Through this mechanism, gambogenic acid modulates EZH2-driven transcriptional repression and epigenetic signaling pathways, making it a valuable tool for studying EZH2-dependent oncogenic processes. In cellular models, it exhibits antiproliferative effects across a range of cancer cell lines, including cervical, erythroleukemic, hepatocellular carcinoma, and melanoma cells, where it induces apoptosis, cell cycle arrest at the G0/G1 phase, and inhibits migration in a concentration-dependent manner, generally within low micromolar activity ranges. In vivo, formulation approaches such as lipid nanoparticle encapsulation have demonstrated tumor growth inhibition in murine cancer models, supporting its utility in preclinical evaluation. Gambogenic acid is therefore widely used in studies investigating epigenetic therapeutics, cancer cell signaling, and drug discovery workflows, with experimental concentrations and dosing regimens tailored to specific assay systems and research objectives.